Search Medical Condition
Please enter condition
Please choose location from dropdown

Forli, Italy Clinical Trials

A listing of Forli, Italy clinical trials actively recruiting patients volunteers.

RESULTS

Found (169) clinical trials

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Subjects should continue on the treatment regimen that the subject was receiving in the prior study. Dose changes of any of the prior therapies subjects were receiving on the previous protocol are allowed after medical monitor approval. The day 1 visit for this study should coincide with the last treatment …

Phase

0.0 miles

Learn More »

Scaffold in Emilia Romagna and in the MAGIC Network

Coronary stents are the default devices for the treatment of coronary artery disease in percutaneous coronary intervention (PCI) according to existing guidelines. However, thrombosis and restenosis are still the main limitations of current permanent metallic stents. In contrast to Bare Metal Stents (BMSs), Drug Eluting Stents (DESs) have a reduced …

Phase N/A

0.0 miles

Learn More »

Contemporary Clinical Management Of Acute Pulmonary Embolism

This is a prospective, non-interventional, multicenter study in patients with acute pulmonary embolism admitted to Cardiology, Emergency and Internal Medicine Departments in Italy. The aim of the study is to assess contemporary management strategies in patients with acute pulmonary embolism in terms of diagnosis, risk stratification, hospitalization and treatment in …

Phase N/A

0.0 miles

Learn More »

rFVIIa in ICH in Patients Treated With Anticoagulants or Anti-Platelets

Intracerebral hemorrhage (ICH) is the deadliest, most disabling, and least treatable form of stroke. Approximately 40% of patients die within 1 month of ICH onset, and two-thirds of survivors never regain functional independence. Though guidelines for supportive care exist, there is currently no treatment that has been shown in a …

Phase

0.0 miles

Learn More »

Myocet Docetaxel & Trastuzumab as 1st Line Treatment of Patients With HER-2/Neu Positive Metastatic Breast Cancer

1. To assess the maximum tolerated dose (MTD) of Myocet at different dosages in combination with Taxotere at the fixed dose of 35 mg/m2 on day 2 and 9 every 21 days and weekly Herceptin as first line therapy in patients affected by HER-2/neu positive metastatic breast cancer 2. To …

Phase

0.0 miles

Learn More »

LTOT in COPD Patients With Moderate Chronic Hypoxemia and Chronic Heart Failure

Long-term oxygen treatment (LTOT) improves survival of COPD patients with severe hypoxemia . The improved survival was proven in COPD patients with severe chronic hypoxemia (PaO2< or = 55 mmHg), providing oxygen was delivered for = or >15 hours/day. Since then, > 15 hours/day LTOT has become the standard treatment …

Phase

0.0 miles

Learn More »

Safety Issues and SurvIval For Medical Outliers

Phase 1 - Patients enrollment (October 2018 - May 2019) Each Investigator will have to record data concerning 70 patients. In particular 40 patients "outliers" (max 10 per month) and 30 patients "control" (max 6 per month). It will be collected clinical and organisational information. The Investigators of the wards …

Phase N/A

0.0 miles

Learn More »

A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis Post Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis

The study is a randomized, controlled phase 3 study comparing the efficacy of pacritinib with P/C therapy in patients with PMF, PPV-MF, or PET-MF (Dynamic International Prognostic Scoring System [DIPSS] risk score of Intermediate-1 to High-Risk), who have had had no or limited exposure to any JAK2 inhibitor or are …

Phase

0.0 miles

Learn More »

Web Based Orthopaedic Sports Medicine Registry

The purpose of this study is to establish an international, web based clinical registry to collect baseline characteristics of patients undergoing orthopaedic, sports medicine, arthroscopy, and related surgery, and the subsequent outcomes and cost-effectiveness associated with the surgical procedures and nonoperative treatments.

Phase N/A

0.0 miles

Learn More »

Study of Pharmacodynamics Pharmacokinetics Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis

This study will investigate the safety and efficacy of VAY736 administered subcutaneously (s.c.) every 4 weeks for 48 weeks. Approximately, 84 subjects will be randomized in a 1:1 ratio on top of local standard of care (SOC), to receive VAY736 or placebo.

Phase

0.0 miles

Learn More »